

参考資料4:臨床論文

- | 番号 | 癌種 | 論文名 |
|----|-------|--|
| 1 | 頭頸部がん | A Phase I study of ONYX-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.
Ganly I, Kirn D, Eckhardt SG. <i>Clinical Cancer Research</i> . 2000; 6: 798-806. |
| 2 | 頭頸部がん | Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer.
Nemunaitis J, Khuri F, Ganly I, et al. <i>JCO</i> . 2001; 19(2): 289-298. |
| 3 | 頭頸部がん | A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.
Khuri FR, Nemunaitis J, Ganly I, et al. <i>Nat Med</i> . 2000 Aug;6(8):879-85. |
| 4 | 頭頸部がん | Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.
Nemunaitis J, Ganly I, Khuri F, et al. <i>Cancer Res</i> . 2000 Nov 15;60(22):6359-66. |
| 5 | 頭頸部がん | Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus.
Xia ZJ, Chang JH, Zhang L, et al. <i>Ai Zheng</i> . 2004 Dec;23(12):1666-70. |
| 6 | 膵臓がん | Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial.
Mulvihill S, Warren R, Venook A, et al. <i>Gene Ther</i> . 2001 Feb;8(4):308-15. |
| 7 | 膵臓がん | A Phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.
Hecht HR, Bedford R, Abbruzzese J, et al. <i>Clinical Cancer Research</i> 2003;9: 555-561. |
| 8 | 膵臓がん | Preliminary study on EUS guided oncolytic adenovirus implantation in patients of non-operative pancreatic cancer.
Zhu Qi. <i>Gastrointestinal Endoscopy</i> . 2009; 69(2): S265. |
| 9 | 膵臓がん | Preliminary study on EUS guided oncolytic adenovirus implantation in patients of advanced pancreatic cancer.
Zhu Q, Xu K, Xia L, et al. <i>Gastrointestinal Endoscopy</i> . 2008; 67(5): S222-3. |
| 10 | 肝臓がん | Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints.
Reid T, Galanis E, Abbruzzese J, et al. <i>Cancer Research</i> 2002;62: 6070-6079 |
| 11 | 肝臓がん | Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies.
Makower D, Rozenblit A, Kaufman H, et al. <i>Clinical Cancer Research</i> . 2003; 9: 693-702. |

- 12 大腸がん Intra-arterial administration of a replication-selective adenovirus (dl1529) in patients with colorectal carcinoma metastatic to the liver: a Phase I trial.
Gene Therapy. 2001; 8: 1618-1626.
- 13 大腸がん Effects of ONYX-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin.
Reid T, Freeman S, Post L, et al. Cancer Gene Therapy. 2005; 12: 673-681.
- 14 大腸がん Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer.
Hamid O, Varterasian ML, Wadler S, et al. JCO. 2003; 21(8): 1498-1504.
- 15 卵巣がん Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 3 weeks in patients with recurrent / refractory epithelial ovarian cancer.
Vasey PA, Shulman LN, Campos E, et al. JCO. 2002;20(6):1562-1569.
- 16 グリオーマ A Phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting
- 17 進行性肉腫 Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas.
Galanis E, Kuno SH, Nascimento AG, et al. Gene Therapy. 2005; 12: 437-445.
- 18 進行性肉腫 Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas. Methods and Molecular Biology. 2009; 542: 705-17.
- 19 進行がん A Phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients.
Nemunaitis J, Senzer N, Sarmiento S, et al. Cancer Gene Therapy. 2007; 14(11): 885-93.
- 20 進行がん Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity.
Nemunaitis J, Cunningham C, Buchana A, et al. Gene Therapy. 2001; 8: 746-759.
- 21 進行がん Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients.
Nemunaitis J, Cunningham C, Tong AW, et al. Cancer Gene Ther. 2003 May;10(5):341-52.
- 22 進行がん Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial.
Lu W, Zheng S, Li XF, et al. World J Gastroenterol. 2004 Dec 15;10(24):3634-8.
- 23 進行がん Phase II clinical study of intratumoral H101, an E1B deleted adenovirus, in combination with chemotherapy in patients with cancer.
Xu RH, Yuan ZY, Guan ZZ, et al. Ai Zheng. 2003 Dec;22(12):1307-10.

- 24 進行がん Safety of an E1B deleted adenovirus administered intratumorally to patients with cancer.
Yuan ZY, Zhang L, Li S, et al. Ai Zheng. 2003 Mar;22(3):310-3.
- 25 温熱療法 Abscopal effect on metastatic tumor induced by oncolytic virus of H101 combining with local heating.
Hu F, Hu XH, Yu P, et al. Ai Zheng. 2006 Aug;25(8):919-24.
- 26 悪性腹水 Oncolytic virus as an agent for the treatment of malignant ascites.
Liu HL, Chen J. Cancer Biother Radiopharm. 2009 Feb;24(1):99-102.
- 27 肺がん Oncolytic adenovirus H101 in combination with vinorelbine / cisplatin chemotherapy for advanced non-small cell lung cancer. Tumor. 2006; 26(7): 613-7.